Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL ER versus FLAGYL I V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL ER versus FLAGYL I V.
FLAGYL ER vs FLAGYL I.V.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
750 mg orally once daily for 10 days for bacterial vaginosis.
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic